Abiopharma

Mobix Labs Signs Transformational Rare Earths Acquisition Agreement, Expanding National Security Platform

OZOP Energy Solutions, Inc. Highlights PEOPLE Magazine Feature on Ballislife HYDRO Investor Egypt Dean

Financial Statements and Related Announcement: Second Quarter and/ or Half Yearly Results

SEALSQ Issues CEO Letter to Shareholders

NeuroSense Issues CEO Letter to Shareholders

ComEd Restores Power to More Than 80 Percent of Customers Impacted by August 11 and 12 Storms

Clinical trial NCT06849869 updates: 1. completion date: 2028-06-30 → 2029-03-30 2. primary completion date: 2028-06-30 → 2029-01-30

Clinical trial NCT06873945 updates: 1. status: ACTIVE_NOT_RECRUITING → RECRUITING 2. completion date: 2026-12-21 → 2028-03-19 3. primary completion date: 2026-12-21 → 2028-03-19 4. enrollment: 550 → 1330 participants 5. enrollment type: ACTUAL → ESTIMATED

Clinical trial NCT06992544 updates: 1. completion date: 2026-07-01 → 2026-11-01 2. primary completion date: 2026-07-01 → 2026-11-01

Clinical trial NCT06252753 updates: 1. start date: 2023-12-20 → 2023-12-19 2. enrollment: 4490 → 4000 participants